Joaquin de Rojas, MD
Ophthalmology · Venice, FLNPI 1619387370
Payments from drug & device makers
Across 372 payments — averaging $1195.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$306K
- Sun Pharmaceutical Industries Inc.$66K
- Lensar, Inc.$32K
- Carl Zeiss Meditec, Inc.$13K
- Nordic Pharma, Inc.$12K
- AbbVie$6K
- plus $11K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 65 | $305,721 |
| Sun Pharmaceutical Industries Inc. | 97 | $65,897 |
| Lensar, Inc. | 16 | $32,494 |
| Carl Zeiss Meditec, Inc. | 13 | $12,515 |
| Nordic Pharma, Inc. | 2 | $11,909 |
| AbbVie(2 entities) | 32 | $5,555 |
| Rxsight Inc | 11 | $3,503 |
| Alcon | 21 | $2,487 |
| Tearlab Corp | 2 | $1,121 |
| Bausch & Lomb Americas Inc. | 39 | $873 |
| Tarsus Pharmaceuticals, Inc. | 12 | $487 |
| Dompe US, Inc. | 10 | $429 |
| Harrow Eye, LLC | 13 | $399 |
| Glaukos Corporation | 6 | $362 |
| Oyster Point Pharma, Inc. | 3 | $188 |
| Novartis | 7 | $173 |
| Amgen | 1 | $123 |
| Apellis Pharmaceuticals, Inc. | 1 | $106 |
| Sight Sciences, Inc. | 6 | $104 |
| Ocular Therapeutix, Inc. | 4 | $97 |
| Dutch Ophthalmic, USA | 2 | $87 |
| Johnson & Johnson Vision Care, Inc. | 1 | $55 |
| Halozyme Inc | 2 | $46 |
| Carl Zeiss Meditec USA, Inc. | 1 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Biotissue Holdings Inc. | 1 | $25 |
| Beaver-visitec International, Inc. | 1 | $25 |
| Kala Pharmaceuticals, Inc. | 1 | $23 |
| Oasis Medical, Inc. | 1 | $17 |
How this compares
$444,883 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Venice
- Patricia StephensonVenice$691K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.